Ocular Therapeutix: Strategic Transformation and Retinal Innovation
Company Overview & Priorities
Ocular Therapeutix, led by Executive Chairman, President & CEO Pravin U. Dugel, is dedicated to improving vision in the real world through innovative ophthalmic solutions.
Mission Statement: To improve vision in the real world.
Transformation into a Retina-Focused Company
Ocular Therapeutix is strategically shifting its focus towards retinal diseases, leveraging its extensive expertise in retina care. Key initiatives include:
-
Proof-of-Concept for AXPAXLI - A promising drug candidate showing effectiveness in treating wet age-related macular degeneration (AMD), non-proliferative diabetic retinopathy (NPDR), and central subfield thickness (CSFT). Data from phase 1 trials demonstrates monotherapy proof-of-concept and potential for best-in-class durability.
-
Regulatory Pathway - Adapting to new FDA guidelines, Ocular Therapeutix has received written agreements for the design of its phase 1 trials, aligning closely with regulatory requirements for treatments of neovascular AMD.
-
Targeting Expansive Markets - Focusing on expansive retinal vascular disease markets, aiming to address unmet needs in vision restoration.
Key Pillars
- World Class Retina Expertise - Leveraging deep understanding and experience in retina care.
- Promising Data for AXPAXLI - Showcasing robust evidence of effectiveness in phase 1 trials.
- De-risking Strategy - Strategically managing risks associated with clinical trial designs and regulatory approvals.
- Targeted Market Expansion - Targeting broader patient populations with retinal vascular diseases.
AXPAXLI: Proof-of-Concept in Phase 1 Trials
- Monotherapy Effectiveness - Demonstrated through improved visual acuity and comparable outcomes to standard of care (SOC) treatments like Eylea in phase 1 trials.
- Duration of Effect - Phase 1 trials show durable effects, potentially outperforming current standards.
Regulatory Adaptation and Timeline
- Initial Design Agreement - Received FDA approval for the initial phase 1 trial design of AXPAXLI for wet AMD.
- Amended Design Approval - Received FDA approval for an amended design, aligning with updated FDA guidelines for neovascular AMD treatments.
- Clinical Trial Timeline - Initiated enrollment in Q1 2023, with the first subjects enrolled in February 2024, targeting completion by Q4 2023.
Ocular Therapeutix is poised to revolutionize the treatment landscape for retinal diseases, combining cutting-edge science with regulatory compliance to deliver effective therapies.
